Guselkumab vs. secukinumab for the treatment of moderate-to-severe psoriasis: a critical appraisal

Br J Dermatol. 2021 Feb;184(2):259-260. doi: 10.1111/bjd.19216. Epub 2020 Jul 1.

Authors

M T Wan¹, J Takeshita^{1

2}

Affiliations

¹ Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
² Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

PMID: 32407562
DOI: 10.1111/bjd.19216

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized*
Double-Blind Method
Humans
Psoriasis* / drug therapy
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
guselkumab
secukinumab